通秘丸预防急性心肌梗死患者便秘的临床观察

目的：观察中成药通秘丸预防急性心肌梗死（Acute myocardial infarction AMI）病人便秘的有效性和安全性。方法：选择笔者所在医院急性心肌梗死住院患者78例,随机分为观察组和对照组各39例,对照组给予急性心肌梗死的常规治疗,必要时开塞露塞肛治疗,观察组在其常规治疗基础上加服小剂量中成药通秘丸,观察两组病人便秘发生率及排便过程中并发症发生情况。结果：观察组病人便秘发生率明显低于对照组（P〈0.05）;观察组病人排便过程中并发症发生率明显低于对照组（P〈0.05）。结论：口服通秘丸预防急性心梗便秘的效果明显,可显著减低AMI患者便秘的发生率,减少由此引发的严重心力衰竭、心脏破裂、心脏猝死等并发症。

Clinical observation on preventing constipation of acute myocardial infarction with Tongmi Wan

Objective： To observe efficacy and safety of Tongmi Wan on constipation of acute myocardial infarction. Methods： 78 patients were randomly divided into the observation group and the control group, each for 39 cases. The control group was given conventional treatment plus glycerine enema sometimes, and the observation group was given conventional treatment plus small dose of Tongmi Wan. The incidence of constipation and complications in the process of defecation were observed in two groups. Results： The incidence of constipation in the observation was obviously lower than that in the control group （P〈0.05）; complications in the process of defecation in the observation was obviously lower than that in the control group （P〈0.05）. Conclusion： Tongmi Wan could obvious prevent constipation of acute myocardial infarction, significantly reduce incidence in AMI patients with constipation and complications, such as heart failure, cardiac rupture, sudden cardiac death.